6-环戊氧基吡啶-3-胺 | 748183-38-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-环戊氧基吡啶-3-胺
• 英文名称: 6-cyclopentyloxy-pyridin-3-ylamine
• 英文别名: 6-cyclopentyloxypyridin-3-ylamine；6-(Cyclopentyloxy)pyridin-3-amine；6-cyclopentyloxypyridin-3-amine
• CAS: 748183-38-2
• 化学式: C₁₀H₁₄N₂O
• mdl: MFCD09737759
• 分子量: 178.234
• InChiKey: WMSWCWLWVISCKC-UHFFFAOYSA-N

物化性质

• 沸点：
  334.4±22.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-环戊氧基吡啶-3-胺 在 sodium acetate 、 sodium hydride 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 49.0h， 生成 2-chloro-7-(6-(cyclopentyloxy)pyridin-3-yl)-5,7-dihydro-6H-pyrrolo[2,3-a]pyrimidin-6-one
  参考文献：
  名称：

  BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF

  摘要：

  本文提供了用于预防或治疗各种病症、紊乱或疾病的化合物、组合物、方法和用途。在某些实施方案中，病症、紊乱或疾病是癌症。

  公开号：

  WO2023241620A1
• 作为产物：
  描述：

  2-氯-5-硝基吡啶 在 palladium 10% on activated carbon 氢气 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 1.02h， 生成 6-环戊氧基吡啶-3-胺
  参考文献：
  名称：

  WO2006/135719

  摘要：

  公开号：

文献信息

• [EN] ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF<br/>[FR] DÉRIVÉS D'ÉTHYNE, COMPOSITIONS PHARMACEUTIQUES ET LEURS UTILISATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012032014A1

  公开（公告）日：2012-03-15

  invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

  这项发明涉及公式I的新化合物，涉及它们作为药物的用途，涉及它们的治疗用途的方法，以及含有它们的药物组合物。
• Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040220191A1

  公开（公告）日：2004-11-04

  The invention relates to substituted N-aryl heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I 1 in which the radicals have the stated meanings, the N-oxides and the physiologically tolerated salts thereof and process for the preparation thereof are described. The compounds are suitable for example as anorectic agents.

  这项发明涉及取代N-芳基杂环化合物及其生理耐受盐和生理功能衍生物。式I的化合物 1 其中基团具有所述含义，其N-氧化物及其生理耐受盐以及其制备方法被描述。这些化合物例如适用作为厌食剂。
• ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS
  申请人：Baindur Nand

  公开号：US20060281772A1

  公开（公告）日：2006-12-14

  The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R 1 , R 2 , R 3 , B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  该发明涉及Formula I的烷基喹啉和烷基喹噁啉化合物： 其中R1、R2、R3、B、Z、G、Q和X如本文所定义，所述化合物的用途为蛋白酪氨酸激酶调节剂，特别是FLT3和/或c-kit和/或TrkB的抑制剂，所述化合物的用途为在细胞或受试者中减少或抑制FLT3和/或c-kit和/或TrkB的激酶活性，以及所述化合物的用途为预防或治疗受试者的细胞增殖紊乱和/或与FLT3和/或c-kit和/或TrkB相关的紊乱。本发明还涉及包括本发明化合物的药物组合物，以及治疗癌症和其他细胞增殖紊乱等疾病的方法。
• SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOPYRIMIDINES KINASE MODULATORS
  申请人：Baumann Andrew Christian

  公开号：US20060281755A1

  公开（公告）日：2006-12-14

  The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from aminopyrimidine compounds of Formula I′: where R 3 , B, Z, r and R 1 are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

  这项发明涉及一种抑制FLT3酪氨酸激酶活性或表达或减少细胞或受试者中FLT3激酶活性或表达的方法，包括给予一种法尼基转移酶抑制剂和一种从式I′的氨基嘧啶化合物中选择的FLT3激酶抑制剂：其中R3、B、Z、r和R1如本文所定义。本发明涵盖了用于治疗处于发展细胞增殖障碍或与FLT3有关的障碍风险（或易感）的受试者的预防和治疗方法。
• AMINOPYRIMIDINES AS KINASE MODULATORS
  申请人：Gaul David Michael

  公开号：US20060281764A1

  公开（公告）日：2006-12-14

  The invention is directed to aminopyrimidine compounds of Formula I: where R 3 , B, Z, Q, p, q and R 1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  该发明涉及式I的氨基嘧啶化合物：其中R3、B、Z、Q、p、q和R1如本文中所定义，该类化合物的用途为蛋白酪氨酸激酶调节剂，特别是FLT3和/或c-kit和/或TrkB的抑制剂，该类化合物的用途是在细胞或主体中减少或抑制FLT3和/或c-kit和/或TrkB的激酶活性，并且该类化合物的用途是用于预防或治疗主体中的细胞增殖紊乱和/或与FLT3和/或c-kit和/或TrkB相关的紊乱。本发明进一步涉及包括本发明化合物的药物组合物以及用于治疗癌症和其他细胞增殖紊乱等疾病的方法。